Busse P.J. Christiansen S.C.

Hereditary angioedema.

N Engl J Med. 382: 1136-1148Bork K. Meng G. Staubach P. et al.

Hereditary angioedema: new findings concerning symptoms, affected organs, and course.

Am J Med. 119: 267-274Proper S.P. Lavery W.J. Bernstein J.A.

Definition and classification of hereditary angioedema.

Allergy Asthma Proc. 41: S03-S07

Hereditary angioedema with normal C1-INH (HAE type III).

J Allergy Clin Immunol Pract. 1: 427-432Magerl M. Germenis A.E. Maas C. et al.

Hereditary angioedema with normal C1 inhibitor: update on evaluation and treatment.

Immunol Allergy Clin N Am. 37: 571-584Veronez C.L. Csuka D. Sheikh F.R. et al.

The expanding spectrum of mutations in hereditary angioedema.

J Allergy Clin Immunol Pract. 9: 2229-2234Bork K. Staubach P. Hardt J.

Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angioedema.

Allergy. 63: 751-757Bork K. Meng G. Staubach P. et al.

Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema.

Transfusion. 45: 1774-1784Hahn J. Hoess A. Friedrich D.T. et al.

Unnecessary abdominal interventions in patients with hereditary angioedema.

J Dtsch Dermatol Ges. 16: 1443-1449Bork K. Hardt J. Witzke G.

Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency.

J Allergy Clin Immunol. 130: 692-697Minafra F.G. Gonçalves T.R. Alves T.M. et al.

The mortality from hereditary angioedema worldwide: a review of the real-world data literature.

Clin Rev Allergy Immunol. 62: 232-239

Pathogenesis of hereditary angioedema: the role of the bradykinin-forming cascade.

Immunol Allergy Clin N Am. 37: 513-525Sharma J. Jindal A.K. Banday A.Z. et al.

Pathophysiology of hereditary angioedema (HAE) beyond the SERPING1 gene.

Clin Rev Allergy Immunol. 60: 305-315de Maat S. Björkqvist J. Suffritti C. et al.

Plasmin is a natural trigger for bradykinin production in patients with hereditary angioedema with factor XII mutations.

J Allergy Clin Immunol. 138: 1414-1423Bork K. Wulff K. Steinmüller-Magin L. et al.

Hereditary angioedema with a mutation in the plasminogen gene.

Allergy. 73: 442-450Bork K. Wulff K. Rossmann H. et al.

Hereditary angioedema cosegregating with a novel kininogen 1 gene mutation changing the N-terminal cleavage site of bradykinin.

Allergy. 74: 2479-2481Bork K. Wulff K. Möhl B.S. et al.

Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation.

J Allergy Clin Immunol. 148: 1041-1048Bafunno V. Firinu D. D'Apolito M. et al.

Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema.

J Allergy Clin Immunol. 141: 1009-1017Ariano A. D'Apolito M. Bova M. et al.

A myoferlin gain-of-function variant associates with a new type of hereditary angioedema.

Allergy. 75: 2989-2992

Treatment of hereditary angioedema.

J Investig Allergol Clin Immunol. 31: 1-16Christiansen S.C. Zuraw B.L.

Hereditary angioedema: on-demand treatment of angioedema attacks.

Allergy Asthma Proc. 41: S26-S29

Hereditary angioedema: long-term prophylactic treatment.

Allergy Asthma Proc. 41: S35-S37Craig T.J. Levy R.J. Wasserman R.L. et al.

Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks.

J Allergy Clin Immunol. 124: 801-808Zuraw B. Cicardi M. Levy R.J. et al.

Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema.

J Allergy Clin Immunol. 126: 821-827Cicardi M. Banerji A. Bracho F. et al.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

N Engl J Med. 363: 532-541Levy R.J. Lumry W.R. McNeil D.L. et al.

EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema.

Ann Allergy Asthma Immunol. 104: 523-529Zuraw B.L. Busse P.J. White M. et al.

Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema.

N Engl J Med. 363: 513-522Longhurst H. Cicardi M. Craig T. et al.

Prevention of hereditary angioedema attacks with a subcutaneous C1 inhibitor.

N Engl J Med. 376: 1131-1140Banerji A. Riedl M.A. Bernstein J.A. et al.

Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial.

JAMA. 320: 2108-2121Zuraw B. Lumry W.R. Johnston D.T. et al.

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial.

J Allergy Clin Immunol. 148: 164-172Gelfand J.A. Sherins R.J. Alling D.W. et al.

Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities.

N Engl J Med. 295: 1444-1448

Critical appraisal of androgen use in hereditary angioedema: a systematic review.

Ann Allergy Asthma Immunol. 114: 281-288Wintenberger C. Boccon-Gibod I. Launay D. et al.

Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients.

Clin Exp Immunol. 178: 112-117Vitrat-Hincky V. Gompel A. Dumestre-Perard C. et al.

Type III hereditary angio-oedema: clinical and biological features in a French cohort.

Allergy. 65: 1331-1336

Triggers and short-term prophylaxis in patients with hereditary angioedema.

Allergy Asthma Proc. 41: S30-S34Zanichelli A. Ghezzi M. Santicchia I. et al.

Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: an observational study.

PLoS One. 15e0230128Farkas H. Zotter Z. Csuka D. et al.

Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor: a long-term survey.

Allergy. 67: 1586-1593Germenis A.E. Margaglione M. Pesquero J.B. et al.

International consensus on the use of genetics in the management of hereditary angioedema.

J Allergy Clin Immunol Pract. 8: 901-911Bork K. Wulff K. Witzke G. et al.

Hereditary angioedema with normal C1-INH with versus without specific F12 gene mutations.

Allergy. 70: 1004-1012Agostoni A. Ayg.ren-Pursun E. Binkley K.E. et al.

Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond.

J Allergy Clin Immunol. 114: S51-S131Busse P.J. Christiansen S.C. Riedl M.A. et al.

US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema.

J Allergy Clin Immunol Pract. 9: 132-150Maurer M. Magerl M. Betschel S. et al.

The International WAO/EAACI guideline for the management of hereditary angioedema: the 2021 revision and update.

Allergy. Betschel S. Badiou J. Binkley K. et al.

The International/Canadian Hereditary Angioedema Guideline.

Allergy Asthma Clin Immunol. 15: 72Pentsuk N. van der Laan J.W.

An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies.

Birth Defects Res B Dev Reprod Toxicol. 86: 328-344Gompel A. Fain O. Boccon-Gibod I. et al.

Exogenous hormones and hereditary angioedema.

Int Immunopharmacol. 78: 106080Brooks J.P. Radojicic C. Riedl M.A. et al.

Experience with intravenous plasma-derived C1-inhibitor in pregnant women with hereditary angioedema: a systematic literature review.

J Allergy Clin Immunol Pract. 8: 1875-1880Fox J. Vegh A.B. Martinez-Saguer I. et al.

Safety of a C1-inhibitor concentrate in pregnant women with hereditary angioedema.

Allergy Asthma Proc. 38: 216-221van Veen H.A. Koiter J. Vogelezang C.J. et al.

Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits.

J Biotechnol. 162: 319-326Moldovan D. Bernstein J.A. Hakl R. et al.

Safety of recombinant human C1 esterase inhibitor for hereditary angioedema attacks during pregnancy.

J Allergy Clin Immunol Pract. 7: 2938-2940Hakl R. Kuklínek P. Krčmová I. et al.

Treatment of hereditary angioedema attacks with icatibant and recombinant C1 inhibitor during pregnancy.

J Clin Immunol. 38: 810-815Farkas H. Kőhalmi K.V. Veszeli N. et al.

First report of icatibant treatment in a pregnant patient with hereditary angioedema.

J Obstet Gynaecol Res. 42: 1026-1028Kaminsky L.W. Kelbel T. Ansary F. et al.

Multiple doses of icatibant used during pregnancy.

Allergy Rhinol (Providence). 8: 178-181Zanichelli A. Mansi M. Periti G.

Icatibant exposure during pregnancy in a patient with hereditary angioedema.

J Investig Allergol Clin Immunol. 25: 447-449

Icatibant [package insert].

() ()

Ecallantide [package insert].

() ()

Lanadelumab [package insert].

() ()

Berotralstat [package insert].

() ()

Ambiguous genitalia in a term female infant due to exposure to danazol in utero.

Am J Dis Child. 136: 474Reschini E. Giustina G. D’Alberton A. et al.

Female pseudohermaphroditism due to maternal androgen administration: 25-year follow-up.

Lancet. 1: 1226

Tranexamic acid: a review of its use in surgery and other indications.

Drugs. 57: 1005-1032

Tranexamic acid [package insert].

() ()Zanichelli A. Azin G.M. Cristina F. et al.

Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.

Orphanet J Rare Dis. 13: 51Riedl M.A. Bygum A. Lumry W. et al.

Safety and usage of C1-inhibitor in hereditary angioedema: Berinert Registry Data.

J Allergy Clin Immunol Pract. 4: 963-971Martinez-Saguer I. Rusicke E. Aygören-Pürsün E. et al.

Characterization of acute hereditary angioedema attacks during pregnancy and breast-feeding and their treatment with C1 inhibitor concentrate.

Am J Obstet Gynecol. 203: 131Bouillet L. Longhurst H. Boccon-Gibod I. et al.

Disease expression in women with hereditary angioedema.

Am J Obstet Gynecol. 199: 484Czaller I. Visy B. Csuka D. et al.

The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey.

Eur J Obstet Gynecol Reprod Biol. 152: 44-49Caballero T. Farkas H. Bouillet L. et al.

International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency.

J Allergy Clin Immunol. 129: 308-320Nielsen E.W. Gran J.T. Straume B. et al.

Hereditary angioedema: new clinical observations and autoimmune screening, complement and kallikrein-kinin analyses.

J Intern Med. 239: 119-130Caballero T. Canabal J. Rivero-Paparoni D. et al.

Management of hereditary angioedema in pregnant women: a review.

Int J Womens Health. 6: 839-848

Danazol [package insert].

() ()Drugs and lactation Database (LactMed) [Internet]. National Library of Medicine (US), Bethesda (MD) ()Farkas H. Martinez-Saguer I. Bork K. et al.

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency.

Allergy. 72: 300-313Pedrosa M. Phillips-Angles E. López-Lera A. et al.

Complement study versus CINH gene testing for the diagnosis of type I hereditary angioedema in children.

J Clin Immunol. 36: 16-18